Drug Approval | January 16, 2023
Granules India’s Gagillapur facility completes USFDA inspection
The company will respond to these observations within the stipulated time period.
The company will respond to these observations within the stipulated time period.
The hospital will have all the modern facilities like modular OT, state of the art medical equipment, labs, etc. It will have OPD and IPD services
APAC to see a reduction in imported surgical robotics
Dr. Reddy’s will manufacture the Active Pharmaceutical Ingredient and finished drug at its facilities approved by USFDA
Under the soon to be launched Heal in India initiative, India aims to provide its health infrastructure for patients abroad and make it a global hub for medical and value-based healthcare for patients from across the world
This will give either party customers access enzyme expertise and assets, resulting in cost-effective, green processing for API manufacturing.
The company was chosen for this transformative exercise due to its deep expertise in the healthcare vertical, coupled with its digital engineering and cloud capabilities, a vast partner network, and long-term relationship with the client
The company is preparing a detailed response to the observations, which will be submitted to the USFDA within the stipulated timelines.
The company has played an important role in the procurement and distribution of emergency medical supplies supporting the Union Health Ministry for Covid–19 pandemic management
Palbociclib has a unique mechanism of action which helps in delaying disease progression when co-administered with hormonal therapies
Subscribe To Our Newsletter & Stay Updated
